NIOX Group (LSE:NIOX) has chosen a tender offer, rather than an ongoing market buyback, to return a large slice of its cash to shareholders. The proposal arrived on the same morning as interim results showing slightly lower revenue. The question is why the board settled on a £12.5 million tender at 80p per share, and what the half-year figures say about its capacity to fund it.

What NIOX does

NIOX Group specialises in point-of-care testing of fractional exhaled nitric oxide, known as FeNO, a measure used in the assessment and management of airway inflammation such as asthma. According to its interim report, the company sells in more than 50 countries across the Americas, Asia-Pacific and Europe, the Middle East and Africa. Its NIOX VERO device is transitioning to NIOX PRO, which has received CE Mark and UK MHRA approval. Revenue comes mainly from clinical customers, with a smaller stream serving pharmaceutical trials. The shares are quoted on AIM, and the company is led by chief executive Jonathan Emms.

The tender offer

On 29 September 2026, NIOX proposed a tender offer to buy back up to 15,625,000 ordinary shares at 80p each, a maximum of £12.5 million and about 3.7% of its issued share capital. The company said the price represented a 22% premium to the previous closing price of 65.6p and a 26.9% premium to the three-month volume-weighted average of 63.1p. Singer Capital Markets Securities will act as principal.

The board linked the move to its stated intention "to return 80% of free Cash Flow to shareholders in the medium term" through dividends and capital returns, and described a tender as an efficient way to distribute surplus capital. It will be funded from existing cash, which the company put at £17.4 million on 31 August 2026, with no debt. The offer opened on 30 September and closes at 1pm on 20 October, with a general meeting in Oxford on 21 October and results due on 22 October. Settlement through CREST is scheduled for 23 to 27 October.

Interim results

The same day, NIOX reported revenue of £24.0 million for the six months to 30 June 2026, compared with £25.2 million a year earlier. Clinical revenue rose 3% on a reported basis to £20.6 million, which the company said was flat at constant currency. Pharma trials revenue fell to £3.4 million from £5.2 million, described as a normalisation after an unusually high 2025. Gross Margin improved slightly to 71% from 70%.

Adjusted EBITDA was £8.3 million against £9.2 million, operating profit was £5.5 million and profit before tax £6.0 million. Adjusted Basic Earnings Per Share was 1.98p, against basic earnings per share of 1.41p. Cash stood at £16.8 million at the end of June, after a £6.5 million Dividend paid in June. The board said it "remains confident of delivering full-year revenue and adjusted EBITDA in line with current consensus market expectations".

Risks and what to watch

Flat clinical revenue at constant currency means growth will depend on adoption of FeNO testing and a smooth transition to NIOX PRO. Pharma trials revenue is lumpy and tied to clinical trial activity. After the tender, the cash balance would fall substantially, leaving less buffer if trading weakens, although the company has no debt. Shareholders must approve the proposal on 21 October, and the take-up will determine the final amount returned.

Conclusion

NIOX is offering to buy back shares at 80p because the board regards its debt-free, cash-generative position as leaving surplus capital, consistent with its aim to return most free cash flow. The interim figures show steady margins and cash, while softer pharma trials revenue and flat clinical growth explain why execution on the new device matters for future returns.